Camlin Fine Sciences Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Camlin Fine Sciences Ltd filed with BSE on 29 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Camlin Fine Sciences reported Q4 revenue of INR424 crores and full-year revenue of INR1,723 crores, with management attributing part of the shortfall to shipping delays and freight disruption linked to a geopolitical conflict. Quarterly EBITDA came in at INR21 crores, or about 5% margin, which management linked to higher freight costs, the Vinpai acquisition's liquidity-related losses, and a switch from methyl to ethyl vanillin production. Management also described the liquidation of CFS Europe, a resulting accounting gain of roughly INR100 crores, and a recent fire incident at the Dahej plant that led to a decision to import hydroquinone rather than continue diphenol manufacturing.
Numbers mentioned
Revenue: INR424 crores (Q4 FY26)
p. 3
“With this, we clocked around INR424 crores of revenue in this quarter.”
Santosh Parab, page 3 of the filed PDF · View the filing
Total revenue: INR1,723 crores (FY26)
p. 3
“The total revenue is INR1,723 crores.”
Santosh Parab, page 3 of the filed PDF · View the filing
EBITDA: INR21 crores (Q4 FY26)
p. 5
“Resultantly, the quarter EBITDA has been INR21 crores, it's 5%.”
Santosh Parab, page 5 of the filed PDF · View the filing
Blends business growth: 17% (FY26)
p. 4
“We have been saying that we will be doing around 20%. We have clocked 17%.”
Santosh Parab, page 4 of the filed PDF · View the filing
Vanillin average realization: more than $12.5 (Q4 FY26)
p. 4
“our average realization for the company for the vanillin has gone up from sub- $11 to more than $12.5 in quarter four”
Santosh Parab, page 4 of the filed PDF · View the filing
Vanillin sales volume: around 320 ton (Q4 FY26)
p. 8
“In quantity, vanillin we sold -- around 320 ton.”
Santosh Parab, page 8 of the filed PDF · View the filing
Loan/debt at year end: around INR670 crores (FY26 year-end)
p. 9
“So at the end of this year, we have around INR670 crores loan.”
Santosh Parab, page 9 of the filed PDF · View the filing
Blends business revenue: INR1,050 crores (FY26)
p. 16
“So in the Blends operation, we closed the year at INR1,050 crores...”
Nirmal Momaya, page 16 of the filed PDF · View the filing
Gain on discontinued operation: around INR100-odd crores (Q4 FY26)
p. 5
“There is a gain booked on loss of control of the company, which is around INR100-odd crores, which we have booked this quarter.”
Santosh Parab, page 5 of the filed PDF · View the filing
Catechol inventory: about 3,000 ton
p. 11
“So it's about in the region of about 3,000 ton.”
Nirmal Momaya, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — 12% to 14% · FY 2027
stated firmly by Nirmal Momaya
p. 12
“EBITDA margins would be between 12% to 14% on an overall basis.”
Nirmal Momaya, page 12 of the filed PDF · View the filing
Revenue — INR2,200 crores to INR2,400 crores · FY 2027
stated firmly by Nirmal Momaya
p. 12
“we should be in the region of between INR2,200 crores to INR2,400 crores.”
Nirmal Momaya, page 12 of the filed PDF · View the filing
Vanillin volume in U.S. — 2,200 to 2,400 metric ton · FY 2027
stated firmly by Nirmal Momaya
p. 10
“our estimate for FY 2027 in the U.S. will be around the 2,200 to 2,400 metric ton.”
Nirmal Momaya, page 10 of the filed PDF · View the filing
Blends business revenue — northwards of INR1,400 crores · FY27
stated firmly by Nirmal Momaya
p. 16
“This year, we are looking at anything an upwards INR1,400 crores for the FY27 in the Blends business.”
Nirmal Momaya, page 16 of the filed PDF · View the filing
Vinpai and Vitafor EBITDA — above breakeven · FY 2027
stated firmly by Nirmal Momaya
p. 16
“We expect Vinpai and Vitafor to be above breakeven EBITDA in FY 2027 for sure.”
Nirmal Momaya, page 16 of the filed PDF · View the filing
European vanillin volume — 1,500 to 1,600 ton · FY27
stated conditionally by Nirmal Momaya
p. 16
“what we had said the 1,500, 1,600 ton for the year, I think we are good for that.”
Nirmal Momaya, page 16 of the filed PDF · View the filing
Blended vanillin realization — $13.5 to $14 · FY 2027
stated conditionally by Nirmal Momaya
p. 9
“So I think it will be around in the range of $13.5 to $14.”
Nirmal Momaya, page 9 of the filed PDF · View the filing
Gross margin — 48% · Q1 FY27
stated conditionally by Nirmal Momaya
p. 13
“I think we'll maintain that margin. There could be 1% up or down, but we should be able to maintain that margin.”
Nirmal Momaya, page 13 of the filed PDF · View the filing
China discontinued operation cash cost — not more than INR7 crores to INR8 crores · next year
stated firmly by Santosh Parab
p. 5
“China still remains under liquidation, but we don't think the cost will be more than INR7 crores to INR8 crores next year.”
Santosh Parab, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the crisis impacted sales and EBITDA but guidance for FY2027 is unchanged.
Answered by Nirmal Momaya
Asked by Hrushikesh Shah: Whether the Middle East crisis changes FY2027 guidance
p. 9
“And -- we are not changing our guidance -- and we are not changing our guidance for FY 2027. We are guiding on the same line.”
Nirmal Momaya, page 9 of the filed PDF · View the filing
Management said equity infusion is a last resort and they are focused on debt options.
Answered by Santosh Parab
Asked by Avnish Tiwari: Whether the company is considering equity capital infusion
p. 10
“Capital infusion is the last resort. We are in the market for debt at this moment.”
Santosh Parab, page 10 of the filed PDF · View the filing
Management indicated employee cost is expected to remain broadly stable going forward.
Answered by Nirmal Momaya
Asked by Rehan: Whether the current cost structure is the peak for employee expenses
p. 12
“No. So I don't think there will be significant changes. It will be in this region..”
Nirmal Momaya, page 12 of the filed PDF · View the filing
Management said logistics disruption is unpredictable and may take a quarter or more to normalize.
Answered by Santosh Parab
Asked by Surya Patra: Outlook on supply chain and logistics disruption into FY27
p. 15
“We feel that this will linger on for some time, at least it will take a quarter to come back to the normal situation.”
Santosh Parab, page 15 of the filed PDF · View the filing
Management said historically such refunds have been split 50-50 between cash and duty adjustment.
Answered by Nirmal Momaya
Asked by Surya Patra: Whether U.S. tariff refund will be received as cash or duty adjustment
p. 17
“50-50. That's what we understand, it normally becomes 50-50.”
Nirmal Momaya, page 17 of the filed PDF · View the filing
Management said they are able to pass on cost increases with a lag and see the outlook as positive.
Answered by Nirmal Momaya
Asked by Surya Patra: Outlook for TBHQ and BHA business given cost pressures
p. 14
“For TBHQ, BHA. It is positive. Yes. For TBHQ, BHA, it is positive, the outlook.”
Nirmal Momaya, page 14 of the filed PDF · View the filing
Risks flagged
Shipping delays and increased freight time impacting sales
p. 3
“This quarter, the sale was impacted by around 20% due to delay in shipments, lack of ships and increased freight time to our markets across the globe.”
Santosh Parab, page 3 of the filed PDF · View the filing
Conflict affecting raw material availability and prices
p. 3
“This conflict also has affected the availability and prices of some of our raw materials.”
Santosh Parab, page 3 of the filed PDF · View the filing
Working capital cycle stress from longer delivery times
p. 3
“The longer delivery time has also impacted our working capital cycle and that paucity of working capital cycle has also percolated in some ways on the pushing of our business and growing of our business in some of the geographies.”
Santosh Parab, page 3 of the filed PDF · View the filing
Sharp rise in phenol raw material prices and inconsistent availability
p. 6
“our basic raw material prices INR85 is now being quoted at more than INR150 per kg and the availability is also not consistent.”
Ashish Dandekar, page 6 of the filed PDF · View the filing
Fire incident at Dahej plant
p. 5
“we had an unfortunate incident, though it was not a fire at Dahej plant.”
Santosh Parab, page 5 of the filed PDF · View the filing
Vinpai liquidity issues weighing on EBITDA
p. 9
“the Vinpai acquisition, there was an EBITDA loss -- a loss at EBITDA level of INR10 crores, which was due to some liquidity issues which Vinpai had, which, of course, we are addressing.”
Nirmal Momaya, page 9 of the filed PDF · View the filing
Rising raw material costs beyond catechol, such as caustic and glycolic acid
p. 13
“Caustic is actually equal in value as catechol is, and that has gone up by literally doubled up in the last -- after the war situation.”
Nirmal Momaya, page 13 of the filed PDF · View the filing
Unpredictable and elevated freight/logistics costs persisting
p. 15
“The overhang remains because even if the situation is, I don't think the logistic price will immediately come down.”
Santosh Parab, page 15 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.